Skip to main content

Palliative Chemotherapy

by: Robert Killeen MD

Is there anyone amongst the readership that can direct me to a list, a compendium of purely "palliative" chemotherapy regimens? I'm looking specifically for any reference on regimens (ie singlets, doublets, etc +/- RT) designed for non-curative symptomatic treatment. I've scanned EPERC, AAHPM, and the Feinberg Palliative Oncology sites, among others, without much success.

The best definition of a palliative chemotherapy regimen I've found had been derived earlier this decade by a European panel (1). Though their focus was on breast cancer their directive seems applicable across the board. Their opinion was that the optimum palliative regimen should control the disease (ie the response rate, RR) in at least 20-30% of patients and increase the progression-free (PFS) and overall survivals (OS). The regimen's toxicities should, ideally, minimally affect performance status while maximally eliminating tumor symptomatology. Quality of life, not curative intent, was foremost in their consensus.

Those who have treated metastatic or recurrent solid tumors recall that, with the exception of testicular cancer, the course is typically that of a "running battle". There are repeated periods of tumor growth and subsequent treatment followed by periods of dormancy.

Because of comorbidities some patients may not be able to tolerate a full course or cycle of chemotherapy. Even with dose attenuation patients may still lose that personal 'physical reserve' that enables them to maintain long term treatment.

A compendium of palliative chemotherapy regimens can be just as useful for patient care as any tome of standard (neo)adjuvant protocols. If anyone knows of such a book or reference please comment.

Thanks,

Reference;
1) Crown J, Dieras V, Kaufmann M, etal. Chemotherapy for metastatic breast cancer - report of a European expert panel. The Lancet Oncology. 2002;3:719-727.

Comments

vandana said…
HELLO,
A VERY GOOD AND SAFE CHEMO WHICH CAN BE USED IN VARIOUS ADVANCED CANCERS(H&N, BREAST, LUNG, ETC),
INJ.METHOTREXATE 50 MG WEEKLY,I/V SLOW BOLUS,WITH CBC MONITORING.THIS CAN BE GIVEN FOR LONG PERIODS OF TIME, TO VERY OLD AND POOR GC PATEINTS.
DR.VANDANA WILLIAMS.ST.STEPHENS HOSPITAL,DELHI.
Anonymous said…
I don’t know if you already know of Betty Ferrell, RN, PhD who is a Research Scientist  at the City of Hope National Medical Center in Duarte, CA.  If such a compendium exists, she would know.  She is the editor of an amazing textbook on Palliative Nursing.  Good Luck!
Anonymous said…
You can't find a protocol because there is no such thing. Chemotherapy produces symptoms, usually more symptoms than it relieves.

Popular posts from this blog

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …

Opening the Black Box of LTACs: Podcast with Anil Makam

What happens in Long Term Acute Care Hospitals, or LTACs (pronounced L-tacs)?  I've never been in one.  I've sent patients to them - usually patients with long ICU stays, chronically critically ill, with a gastric feeding tube and a trach for ventilator support.  For those patients, the goals (usually as articulated by the family) are based on a hope for recovery of function and a return home.

And yet we learn some surprising things from Anil Makam, Assistant Professor of Medicine at UCSF.  In his JAGS study of about 14,000 patients admitted to LTACHs, the average patient spent two thirds of his or her remaining life in an institutional settings (including hospitals, LTACs and skilled nursing facilities).  One third died in an LTAC, never returning home.

So you would think with this population of older people with serious illness and a shorter prognosis than many cancers, we would have robust geriatrics and palliative care in LTACs?  Right? Wrong.

3% were seen by a geriatrici…

Length of Stay in Nursing Homes at the End of Life

One out of every four of us will die while residing in a nursing home. For most of us, that stay in a nursing home will be brief, although this may depend upon social and demographic variables like our gender, net worth, and marital status. These are the conclusions of an important new study published in JAGS by Kelly and colleagues (many of whom are geripal contributors, including Alex Smith and Ken Covinsky).

The study authors used data from the Health and Retirement Study (HRS) to describe the lengths of stay of older adults who resided in nursing homes at the end of life. What they found was that out of the 8,433 study participants who died between 1992 and 2006, 27.3% of resided in a nursing home prior to their death. Most of these patients (70%) actually died in the nursing home without being transferred to another setting like a hospital.

 The length of stay data were striking:

the median length of stay in a nursing home before death was 5 months the average length of stay was l…